Mabxience Sets Out Investment Plans Under Fresenius Ownership

New Bioreactor At Genhelix Site In Spain Is A Milestone For Biosimilars Developer

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.